Androgenetic Alopecia: A Clinic Treatment Protocol

Part of the PRO EXO Professional Series — clinical-grade exosome vials for hair transplant surgeons, dermatologists, and aesthetic clinics.

Androgenetic alopecia (AGA) is the most common presentation a hair clinic sees, and also the one where outcomes vary most with how structured the clinic's approach is. A clear androgenetic alopecia treatment protocol — assessment, staging, pathway selection, and review — turns an unpredictable consultation into a repeatable clinical service.

This guide outlines such a framework and shows where exosome scalp vials fit alongside conventional therapy. It assumes a clinical setting and is not a substitute for individual medical judgement or, where indicated, systemic prescribing.

Start with assessment and staging

Before any treatment decision, the protocol begins with assessment: pattern classification (Norwood-Hamilton for men, Ludwig or Sinclair for women), trichoscopy to confirm miniaturisation and rule out other causes, a history screening for non-androgenetic contributors (thyroid, iron, medication, stress-related shedding), and standardised baseline photography.

Photography matters enormously: AGA changes are slow, and without consistent baseline images neither clinic nor patient can judge progress fairly. Staging drives expectation-setting — early AGA with preserved follicles responds very differently from advanced miniaturisation.

Separate the male and female pathways

AGA is not one condition with one protocol. For men, the pattern is typically frontal and vertex; conventional first-line medical therapy is well established, and in-clinic procedures are layered on top for patients who want to accelerate results or prefer non-systemic options. A professional AGA treatment vial for men — an exosome regeneration vial applied in-clinic — fits here as an adjunct alongside the patient's medical regimen.

For women, the pattern is usually diffuse thinning over the crown with a preserved frontal hairline. Female AGA more often warrants screening for contributing factors, and some systemic options used in men are unsuitable. In-clinic exosome support is attractive precisely because it is non-systemic — letting the clinic offer an active treatment to women who cannot or prefer not to use certain medications.

Ossome's MINOX PRO EXO line is built around this split — Gen Men and Gen Fem, plus Envigro Men and Envigro Fem — so the clinic matches the vial to the patient's sex and pattern rather than using a single generic formula.

Build the in-clinic procedure protocol

For patients who opt for in-clinic treatment, a typical course is an induction phase followed by maintenance: an induction series of sessions spaced two to four weeks apart, pairing an exosome regeneration vial with a delivery device (microneedling, electroporation, or roller), followed by maintenance sessions at longer intervals once a response is established.

Exact spacing should follow your clinic's protocol and the patient's response — there is no single universal schedule. The principles that hold: standardised dosing per session, consistent technique, and device-assisted delivery, because a topical AGA vial applied to intact scalp without channelling will under-deliver. Throughout, the in-clinic procedure complements rather than replaces the patient's ongoing medical therapy.

A sample staged protocol

Adapt to your clinic. This is a framework, not a fixed prescription.

Managing expectations and review

AGA is a chronic, progressive condition — even a well-run protocol manages rather than cures it, and stopping treatment generally means resumption of the underlying process. Scheduled review with side-by-side photography against baseline, and clear communication that maintenance is ongoing, keep patients on track. Review is also where the clinic decides whether to adjust session frequency, add an adjacent indication (for example, an AZOLEI vial for a seborrheic component), or escalate medical therapy.

Sourcing for an AGA service line

A clinic running an AGA service needs a dependable supplier of aesthetic clinic hair loss treatment vials — consistent batches, sex-specific formulas, and clear protocol guidance. Worth noting how Ossome positions the range: not on exosome count (a marketing number, not a clinical one) but on purity, quality, and the blend of biologics, with a plant-derived source that is the most ethical and legal option for scalp use. Ossome's PRO EXO MINOX range is Singapore-made, plant-derived, clinic-exclusive, and supplied with protocol support across Singapore, Malaysia, and Indonesia.

Related clinical guide

Post-Hair-Transplant Scalp Care: A Clinical Protocol Guide →